No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MEDP Medpace
- 421.310
- -2.650-0.63%
Close Jul 19 16:00 ET
- 426.030
- +4.720+1.12%
Post 17:18 ET
13.05BMarket Cap42.95P/E (TTM)
427.275High419.640Low195.13KVolume421.940Open423.960Pre Close82.48MTurnover0.77%Turnover Ratio47.44P/E (Static)30.98MShares459.77052wk High19.44P/B10.74BFloat Cap227.21052wk Low--Dividend TTM25.50MShs Float459.770Historical High--Div YieldTTM1.80%Amplitude21.760Historical Low422.703Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Notable Earnings After Monday's Close
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
In the latest market close, Medpace (MEDP) reached $443, with a +1.84% movement compared to the previous day.
Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating
Medpace Holdings (MEDP) has an average rating of outperform and price targets ranging from $296 to $480, according to analysts polled by Capital IQ.Price: 402.80, Change: +0.40, Percent Change: +0.10
Medpace Holdings Is Maintained at Outperform by Baird
Medpace Holdings Is Maintained at Outperform by Baird
Comments
Investors expect Medpace Holdings to outperform the market, hence its high P/E ratio. Strong future growth anticipation makes investors pay more for the stock, supporting the share price.
The Price Is Right For Medpace Holdings, Inc. (NASDAQ:MEDP) 1
Medpace Holdings' robust conversion of profit to free cash flow is promising. Its underlying earnings potential may even surpass the statutory profit. Its earnings per share have seen a remarkable growth over the past three years.
1
Medpace Holdings' market sentiment remains steady, mirroring EPS growth. The stock's recent performance shows improvement, with a 90% shareholder return over the last year, surpassing the five-year TSR of 41% per year. The strong share price momentum suggests a closer look at the stock may be worthwhile.
Medpace's high P/E is backed by its forecast growth being higher than the wider market. Investors are quite confident in the company's future earnings and seem willing to pay more for the stock, suggesting a bullish outlook.
Insider selling at current price (US$274) is less worrying, but there were no purchases over the past year to boost confidence. A high level of insider ownership often implies interests of all shareholders are considered, though recent history of share sales triggers some hesitation.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg